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Abstract 
Background: The incidence of melanoma is on 
the rise in the United States and is particularly 
prevalent among women of childbearing age. 
Obtaining a complete history and understanding 
the unpredictable behavior of melanoma is 
essential to make the diagnosis of recurrent 
disease during pregnancy. 
Case: A 35-year-old G2P1 at 23 weeks and 1 
days’ gestation with a remote history of (treated) 
cutaneous melanoma underwent an exploratory 
laparotomy for small bowel obstruction. 
Pathology was consistent with recurrent 
metastatic melanoma. 
Conclusion: Metastatic melanoma diagnosed 
during pregnancy is rare. There are no 
guidelines on how or when to proceed with 
treatment of metastatic disease or delivery of the 
fetus. Immunotherapy is changing the 
management of melanoma and is extending life 
expectancy. The significant survival benefits for 
mother with immunotherapy may outweigh the 
risks of preterm delivery for the baby. 
1University of Iowa Carver College of Medicine, 
Iowa City, Iowa 
2University of Iowa Hospitals and Clinics, 
Department of Internal Medicine, Iowa City, Iowa 
3University of Iowa Hospitals and Clinics, 
Department of Obstetrics and Gynecology, Iowa 
City, Iowa 
 
Introduction 
Melanoma is the most fatal form of skin 
cancer and is the sixth most common 
malignancy diagnosed in women.1 The 
incidence has risen more than any other 
type of cancer in the last 50 years.2 
Melanoma is particularly prevalent 
among women of childbearing age and 
is a common malignancy diagnosed in 
pregnancy, accounting for 8% of all 
malignancies arising during gestation.3,4  
About one third of patients diagnosed 
with melanoma will have a recurrence 
later in life.5 Although it is rare, 
recurrence can present many years later 
with metastatic disease, with a historical 
5-year survival rate of less than 5%.2  
There are few cases in the literature in 
which a patient presents with metastatic 
melanoma during pregnancy. The 
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majority of cases are diagnosed as a 
clinically localized skin lesion; few cases 
present as advanced stage disease, 
therefore it is unlikely to be included on 
the list of differential diagnoses. This 
disease has serious consequences for 
both mother and fetus. We present a 
unique case of small bowel obstruction 
in the second trimester of pregnancy 
consistent with recurrent metastatic 
melanoma. Melanoma most commonly 
metastasizes to the lung, liver, bone and 
brain and is the most common 
malignancy to metastasize to the 
placenta and fetus, although this is 
exceptionally rare.1,5 It can be 
diagnosed early in symptomatic 
presentation with the appropriate 
imaging, but can be overlooked.  It is 
integral to patient care that a complete 
history is obtained and that clinicians 
understand the variable and 
unpredictable behavior of melanoma as 
it continues to become more prevalent. 
Case 
In January 2016, a 35-year-old woman 
at 23 weeks and 1-day gestation 
presented to a local hospital with 
intractable nausea, vomiting, diffuse 
abdominal pain and a 10-lb weight loss 
since her first trimester. She reported 
having intermittent nausea, vomiting and 
abdominal cramping for the past two 
months and was hospitalized overnight 
early in the course for “gastritis.” 
Symptoms were thought to be related to 
pregnancy and were treated 
accordingly. On presentation, she was 
afebrile but tachycardic. Her physical 
exam was significant for an acute 
abdomen with rebound tenderness and 
guarding. Abdominal x-ray was 
concerning for small bowel obstruction. 
Chest x-ray revealed a left mid lung 
lesion measuring 4.0 x 3.8 cm. The 
patient’s past medical history was 
significant for BRAF negative melanoma 
diagnosed in 2005 on the right shoulder 
at an outside hospital. Breslow depth 
and staging information was not 
available. She had a wide local excision 
and negative sentinel node biopsy that 
required no adjuvant therapy. She had 
been followed by dermatology 
biannually with the most recent skin 
exam in the spring of 2015 at which time 
she had a premalignant lesion excised 
from her right ankle. 
The patient was transferred to a local 
tertiary care center and underwent an 
exploratory laparotomy. Intraoperatively, 
a mass within the small bowel causing 
an intussusception was excised and the 
intussusception was reduced. No bowel 
resection was performed. Multiple liver 
nodules were seen and a superficial 
lesion was excised by wedge biopsy 
and many enlarged lymph nodes were 
excised from the mesentery. Pathology 
of the small bowel mass and liver lesion 
was consistent with BRAF negative 
metastatic melanoma.  Lymph nodes 
were negative.  
Following surgery, she presented to our 
department at 25 weeks and 2 days’ 
gestation for a treatment plan. The 
neonatal intensive care unit was 
consulted to discuss preterm delivery 
and fetal viability. Due to the urgent 
need for treatment and the availability of 
new immunotherapy, the patient opted 
for preterm delivery in the 27th week of 
gestation. A full course of corticosteroids 
was given for lung maturity prior to 
delivery. Patient underwent an 
uncomplicated classical cesarean 
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section due to breech presentation of a 
male fetus weighing 1223 grams at 27 
weeks 4 days’ gestation. Apgars were 7 
and 8 at 1 minute and 5 minutes 
respectively and the neonate was 
transferred to the neonatal intensive 
care unit. Placenta evaluation by 
pathology was negative for melanoma 
metastasis. The baby did well and was 
discharged home from the neonatal 
intensive care unit on day of life 66 with 
a weight of 2860 grams. 
A positron emission tomography–
computed tomography (PET/CT) scan 
three days following delivery showed 
significant lesions in the liver, left lung 
and gastric outlet. Brain magnetic 
resonance imaging (MRI) was negative 
for brain metastasis.(Figure1, Figure 2)  
Pre-Immunotherapy PET/CT scans 
 
Figure 1: Chest PET CT, notable for 
left lung lesion 
 
Figure 2: Abdominal PET/CT, notable 
for several liver lesion 
The patient was started on an 
immunotherapy regimen of nivolumab 
(1mg/kg) and ipilimumab (3mg/kg) two 
weeks following delivery. She received 
combination therapy every three weeks 
followed by nivolumab alone every 2 
weeks per the standard of care. A 
repeat PET/CT scan after four and eight 
cycles of treatment revealed partial 
response with smaller lesions and 
significantly less fludeoxyglucose (FDG) 
uptake; no new lesions were noted.  
Post 24 cycles of immunotherapy 
PET/CT scans 
 
Figure 3: Chest PET/CT, notable for 
small lung lesion with minimal FDG 
uptake 
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Figure 4: Abdominal PET/CT, notable 
for several hyperdense hepatic 
lesions with no FDG uptake 
A repeat PET/CT scan after 24 cycles 
showed a stable, significantly improved 
from baseline, lung lesion with low-level 
FDG uptake and several hyperdense 
hepatic lesions with no FDG uptake, 
consistent with treated 
metastases.(Figure 3, Figure 4) She 
tolerated therapy well with minor 
gastrointestinal side effects.  
Discussion 
Many studies have assessed whether 
pregnancy affects the prognosis and 
survival of women diagnosed with 
clinically localized melanoma during 
gestation. The consensus is that 
pregnancy does not adversely impact 
the prognosis or survival of women with 
localized cutaneous disease.6 Due to 
the rarity of advanced stage disease on 
presentation, there are few cases in the 
literature in which a patient presents 
with metastatic melanoma during 
pregnancy. Therefore, there are no 
guidelines on how or when to proceed 
with treatment of the disease or delivery 
of the fetus. In the past, most women 
diagnosed with metastatic melanoma 
during pregnancy have either delivered 
at term and had poor outcomes with 
mortality within 12 months from 
metastatic treatment refractory disease 
or opted for pregnancy termination.7 
There has been one previously 
published case report in which a woman 
was delivered prematurely at 28 weeks, 
received combination chemotherapy but 
died four months after delivery. Sadly, 
the baby died of septicemia at three 
months of age, a common complication 
of preterm delivery.8 To our knowledge, 
this is the first case in the literature in 
which the survival benefits of 
immunotherapy outweighed the risks of 
preterm delivery at 27 weeks and 
resulted in positive outcomes for mother 
and baby.  
It is common for pregnant women to 
present for care for fatigue, nausea, 
vomiting and abdominal pain during 
pregnancy and the differential diagnosis 
should be broad. It is imperative that a 
thorough history is completed, including 
past medical history of remote malignant 
disease as it can manifest many years 
later with detrimental effects to pregnant 
women and their fetus. Both patients 
and healthcare providers often do not 
recognize persistent symptoms as 
features of recurrence and the early 
presentation of a more serious 
diagnosis. The majority of melanoma 
recurrence occurs in the first three years 
(early recurrent); less than 7% of 
recurrences occur 10 or more years 
(late recurrent) after initial diagnosis.5,9 
Thus, presentation to care is delayed 
and the diagnosis is missed initially by 
clinicians.    
The management for metastatic 
melanoma has changed dramatically 
over the past 5 years as new targeted 
immunotherapies have become 
available. The targeted BRAF inhibitors, 
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dabrafenib and vemurafenib, are now 
FDA approved. BRAF is a human proto-
oncogene that makes the protein B-raf 
and is commonly seen in many different 
cancer types, including 50% of 
melanomas.10 There is one published 
case report in which vemurafenib 
therapy was initiated during pregnancy 
for BRAF positive metastatic melanoma. 
While the fetus did well despite 
premature birth at 30 weeks, there was 
a poor maternal outcome with death 
about two months following delivery due 
to rapidly progressive metastatic 
disease.11 Among the immunotherapy 
agents, ipilumumab (a cytotoxic T-
lymphocyte-associated antigen 4 
[CTLA-4] checkpoint inhibitor) was FDA 
approved in 2011 and was the first 
agent to demonstrate fairly good activity 
with an overall 3-year survival rate of 
20% in patients with metastatic 
melanoma.12 More promising results 
with less toxic adverse events are 
achieved with the newer generation PD-
1 (programmed death 1) checkpoint 
inhibitors, nivolumab and 
pembrolizumab, both were approved for 
the treatment of metastatic melanoma 
by the FDA in 2014. These therapies 
have shown improved objective 
responses in 30% of patients while 
combination therapy with nivolumab and 
ipilumumab has resulted in significantly 
longer progression-free survival and 
objective response rates in 50 to 60% of 
patients with metastatic disease.13,14 
Although this new immunotherapy has 
not been studied in pregnancy, the 
positive survival outcomes, especially in 
BRAF negative disease, have proven 
the importance of treating metastatic 
melanoma aggressively and may be an 
indication for preterm delivery. The one-
year national survival rate for an infant 
delivered at 27 weeks is about 90%.15  
Conclusions 
We hope this case emphasizes the 
significance of taking a complete history 
and serves to remind clinicians of the 
unpredictable behavior of recurrent 
melanoma as well as the importance of 
considering it when forming a differential 
diagnosis. Early diagnosis can change 
the clinical management of pregnancy 
and can save the life of the mother and 
fetus. Preterm delivery may be indicated 
in the future as new melanoma 
therapies have shown improved 
maternal survival outcomes in a 
previously dismal disease. It is 
imperative that care is referred to a 
tertiary center with the appropriate 
multidisciplinary team in a timely 
manner. 
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